De Maeseneer D J, Lambert B, Surmont V, Geboes K, Rottey S W H
Diensten Medische Oncologie, Universitair Ziekenhuis Gent, Gent, Belgium.
Acta Clin Belg. 2010 Sep-Oct;65(5):291-9. doi: 10.1179/acb.2010.065.
Current response guidelines for the treatment of solid tumours are based on CT criteria. Over the last decades new techniques have emerged to evaluate cancer therapy. FDG-PET scanning is a more functional imaging technique, which can measure differences in metabolic activity. Although it has a low specificity, studies show that it can outperform classical CT scanning criteria. Especially in lung, breast and oesophageal cancer it can predict response earlier in the neo-adjuvant setting. This could reduce the use of ineffective cancer therapies, reducing costs and patient toxicity, and direct patients sooner towards effective therapy. The main problem with FDG-PET remains the difficulty in defining thresholds for response, as there is clearly a lack in large prospective randomized studies validating the use of FDG-PET in response guidelines.We give an overview of data on response prediction in solid tumours by the application of PET.
目前实体瘤治疗的反应指南是基于CT标准制定的。在过去几十年中，出现了一些新技术来评估癌症治疗效果。FDG-PET扫描是一种更具功能性的成像技术，它可以测量代谢活性的差异。尽管其特异性较低，但研究表明它在性能上优于传统的CT扫描标准。特别是在肺癌、乳腺癌和食管癌中，它可以在新辅助治疗环境中更早地预测反应。这可以减少无效癌症治疗的使用，降低成本和患者毒性，并使患者更快地接受有效治疗。FDG-PET的主要问题仍然是难以确定反应阈值，因为显然缺乏大型前瞻性随机研究来验证FDG-PET在反应指南中的应用。我们概述了通过PET应用对实体瘤反应预测的数据。
